- Home
- ALMS vs ATAI Comparison
ALMS vs ATAI Comparison
Compare ALMS & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALMS
- ATAI
- Stock Information
- Founded
- ALMS 2021
- ATAI 2018
- Country
- ALMS United States
- ATAI Germany
- Employees
- ALMS N/A
- ATAI N/A
- Industry
- ALMS
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- ALMS
- ATAI Health Care
- Exchange
- ALMS NYSE
- ATAI Nasdaq
- Market Cap
- ALMS 402.6M
- ATAI 444.7M
- IPO Year
- ALMS 2024
- ATAI 2021
- Fundamental
- Price
- ALMS $4.10
- ATAI $3.47
- Analyst Decision
- ALMS Strong Buy
- ATAI Strong Buy
- Analyst Count
- ALMS 6
- ATAI 3
- Target Price
- ALMS $19.80
- ATAI $13.33
- AVG Volume (30 Days)
- ALMS 692.8K
- ATAI 6.6M
- Earning Date
- ALMS 08-12-2025
- ATAI 08-12-2025
- Dividend Yield
- ALMS N/A
- ATAI N/A
- EPS Growth
- ALMS N/A
- ATAI N/A
- EPS
- ALMS N/A
- ATAI N/A
- Revenue
- ALMS $17,389,000.00
- ATAI $1,863,000.00
- Revenue This Year
- ALMS N/A
- ATAI $423.05
- Revenue Next Year
- ALMS N/A
- ATAI N/A
- P/E Ratio
- ALMS N/A
- ATAI N/A
- Revenue Growth
- ALMS N/A
- ATAI 572.56
- 52 Week Low
- ALMS $2.76
- ATAI $1.03
- 52 Week High
- ALMS $13.20
- ATAI $4.00
- Technical
- Relative Strength Index (RSI)
- ALMS N/A
- ATAI 63.60
- Support Level
- ALMS N/A
- ATAI $3.06
- Resistance Level
- ALMS N/A
- ATAI $3.70
- Average True Range (ATR)
- ALMS 0.00
- ATAI 0.28
- MACD
- ALMS 0.00
- ATAI 0.01
- Stochastic Oscillator
- ALMS 0.00
- ATAI 62.68
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.